Findings from a preclinical study demonstrate that Omomyc—the only direct MYC inhibitor to have successfully completed a ...

Results from a VHIO-led study show that MYC targeting by Omomyc induces tumor DNA damage in patient-derived preclinical ...

Bladder cancer might be caused by our cell's response to a common virus which infects nearly everyone in childhood, according to new research led by ...

This SNO 2025 presentation represents the second abstract from Rakovina Therapeutics at the conference and reflects the Company’s ongoing research efforts in the field of DNA-damage-response (DDR) ...

On November 18, 2025, the Company announced that its President & CSO, Prof. Mads Daugaard, has been invited to present and ...

Detailed price information for Rakovina Therapeutics Inc (RKV-X) from The Globe and Mail including charting and trades.

Detailed price information for Amicus Therapeutics (FOLD-Q) from The Globe and Mail including charting and trades.

New tools that create ultra-precise maps of our tissues are transforming our ability to diagnose and cure once-fatal ...

Personalised cell therapy developer Aspen Neuroscience added $115 million to its cash reserves with a Series C that included ...

We interviewed doctors and experts to learn everything you need to know about the best NMN supplements for longevity, energy, and skin health ...

Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies ...

Hope of finding survivors has dwindled, with many residents of the Wang Fuk Court towers still unaccounted for. Eight more ...